Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00657904 |
The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.
Condition | Intervention | Phase |
---|---|---|
Non-Metastatic Prostate Cancer |
Drug: Bicalutamide Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer. |
Enrollment: | 3618 |
Study Start Date: | August 1995 |
Study Completion Date: | September 2008 |
Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Bicalutamide
150mg daily
|
2: Placebo Comparator | Drug: Placebo |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Principal Investigator: | William See | Medical College of Wisconsin |
Principal Investigator: | David G. McLeod | Walter Reed Army Medical Center |
Responsible Party: | AstraZeneca ( Tom Morris - Medical Science Director ) |
Study ID Numbers: | D6876C00023, 7054IL/0023 |
Study First Received: | April 7, 2008 |
Last Updated: | January 7, 2009 |
ClinicalTrials.gov Identifier: | NCT00657904 |
Health Authority: | United States: Food and Drug Administration; Canada: Canadian Institutes of Health Research; Canada: Health Canada |
androgen antagonists prostate neoplasms |
Prostatic Diseases Genital Neoplasms, Male Bicalutamide |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Androgen Antagonists Neoplasms Neoplasms by Site Antineoplastic Agents Therapeutic Uses |
Hormone Antagonists Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Pharmacologic Actions |